Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cepheid Reaffirms FY 2012 Revenue Guidance-Conference Call
Cepheid announced that for fiscal 2012, it expects total revenue to be approximately $333 million.
Latest Key Developments in Advanced
- Hologic Inc Receives FDA Approval For New Low-dose 3D Mammography (Breast Tomosynthesis) Solution For Breast Cancer Screening
- Echo Therapeutics Inc Announces Institutional Review Board (IRB) Approval For Clinical Trial Of Symphony CGM System
- Neovasc Inc Announces Registry Data Presented At Europcr 2013 Confirms the Neovasc Reducer Improves Cardiovascular Parameters In Refractory Angina Patients
- Elekta AB's Chairman Akbar Seddigh Declines Reelection
- Share this
- Link this
- Digg this
Follow Reuters